Nurix Therapeutics Inc. (NRIX)
NRIX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$22.13
-0.14% on the day
Market cap
$2.3B
Mid cap
Revenue · 2025
$84.0M
+54.0% on 2024
Net income · 2025
-$264.5M
-314.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NRIX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001549595 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $84.0M |
| Net income | -$264.5M |
| Operating income | -$285.7M |
| Net margin | -314.9% |
| Operating margin | -340.2% |
| Revenue growth | +54.0% |
| Cash | $247.0M |
| Total assets | $688.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 27.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-06 |
| Latest annual report | 10-K | 2026-01-28 |
| Latest quarterly / interim | 10-Q | 2026-10-13 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-03-27 |
Source: SEC EDGAR submissions feed, 551 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.4% |
| 1 month | -5.4% |
| 3 months | +1.9% |
| Year to date | +23.9% |
| 1 year | +141.8% |
| From 52-week high | -15.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare Inc. | $48.50 | -1.02% | $2.3B |
| HCM | HUTCHMED (China) Limited | $13.50 | -1.32% | $2.4B |
| MBX | MBX Biosciences Inc. | $49.00 | -5.80% | $2.4B |
| BHC | Bausch Health Companies Inc. | $5.89 | -0.68% | $2.2B |
| LQDA | Liquidia Corporation | $26.81 | -3.11% | $2.4B |
| NAMS | NewAmsterdam Pharma Company N.V. | $20.19 | -4.99% | $2.4B |
| AUPH | Aurinia Pharmaceuticals Inc | $16.36 | -1.15% | $2.2B |
| IRON | Disc Medicine Inc. | $56.60 | -6.42% | $2.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier